Product name: Forsythoside H
Synonym name:
Catalogue No.: BP2012
Cas No.: 1178974-85-0
Formula: C₂₉H₃₆O₁₅
Mol Weight: 624.592
Botanical Source:
Physical Description:
Type of Compound:

Purity: 95%~99%
Analysis Method: HPLC-DAD or/and HPLC-ELSD
Identification Method: Mass, NMR
Packing: Brown vial or HDPE plastic bottle
The product could be supplied from milligrams to grams. Inquire for bulk scale.
We provide solution to improve the water-solubility of compounds, thereby facilitating the variety of activity tests and clinic uses.

For Reference Standard and R&D, Not for Human Use Directly.

HPLC of Forsythoside H

Storage conditions：Short-term storage at 2~8℃, long-term storage at -20 ~ -80℃

Introduction/Overview

Natural products have always been an important source of drug discovery and development, particularly demonstrating unique value in the fields of anti infection, anti-inflammatory, and immune regulation. Phenylethanoid glycosides (PhGs), as a class of secondary metabolites widely present in the plant kingdom, have attracted much attention due to their structural diversity and significant biological activity. Among them, Forsythoside H is derived from the Oleaceae plant Forsythia suspensa（Forsythia suspensa A type of caffeoyl phenylethanoid glycoside (CPG) isolated from (Thunb.) Vahl. As one of the important active ingredients in Forsythia suspensa, Forsythia suspensa glycoside H has gradually revealed its multifaceted pharmacological potential in recent years, especially in antiviral, anti-inflammatory, and immunomodulatory effects, making it a molecular entity worthy of further exploration in the field of natural product pharmacology.

Forsythia suspensa, as a traditional Chinese medicine, has the effects of clearing heat and detoxifying, reducing swelling and dispersing nodules. It is commonly used to treat diseases such as wind heat, cold, abscess, swelling and toxin. Modern pharmacological research has confirmed that Forsythia suspensa extract and its active ingredients have broad-spectrum antibacterial, antiviral, anti-inflammatory, and antioxidant activities. Forsythia suspensa glycoside H, as a relatively low content but significantly active component in Forsythia suspensa, started its research relatively late, but has shown unique biological effects. Compared with Forsythoside A, which belongs to the same genus, Forsythoside H has slight structural differences, which may lead to different characteristics in target selectivity and pharmacological activity intensity.

At present, research on Forsythia suspensa glycoside H on a global scale is still in its early stages, but existing research data suggests that this compound has potential inhibitory effects in the field of antiviral activity, especially against the replication processes of herpesviruses (such as herpes simplex virus HSV) and retroviruses (such as human immunodeficiency virus HIV). In addition, its anti-inflammatory activity is closely related to the regulation of key inflammatory enzyme activities such as myeloperoxidase (MPO). This article aims to systematically review the chemical structure, plant origin, pharmacological activity, mechanism of action, pharmacological characteristics, and clinical application prospects of Forsythia suspensa glycoside H, in order to provide comprehensive scientific basis for the in-depth development and utilization of this natural product.

Chemical structure and physicochemical properties

The chemical structure of Forsythia suspensa glycoside H belongs to the typical caffeoyl phenylethanoid glycoside class. Its core structure consists of three parts: a phenylethanolic glycoside (usually hydroxytyrosol or similar), a caffeoyl group, and one or more sugar groups (usually glucose and xylose). Specifically, the molecular formula of Forsythia suspensa glycoside H is C ₂₉ H ∝₆ O ₁₅, with a molecular weight of 624.5920 g/mol. Its structural feature is that the caffeoyl group is connected to specific positions of the sugar group through ester bonds, while the phenylethanolic glycoside is connected to the sugar group through glycosidic bonds. This complex glycosidic structure endows the molecule with unique physicochemical properties and biological activity.

From the perspective of physical and chemical properties, Forsythia suspensa glycoside H exhibits typical hydrophilic characteristics. Its lipid water partition coefficient (LogP) is 0.2622, indicating that the compound tends to partition between the aqueous and lipid phases towards the aqueous phase, meaning it has some water solubility but poor lipid solubility. This characteristic is closely related to the presence of multiple hydroxyl and sugar structural units in its molecule. Its water solubility (LogS) value is 5.2012, further confirming its relatively good solubility in water, which is beneficial for its absorption and transport in organisms, but may also limit its transmembrane penetration ability. The Topological Polar Surface Area (TPSA) is as high as 245.2900 Å ², far exceeding the recommended upper limit of 140 Å ² for oral medications. A high TPSA value usually indicates that the molecule has strong polarity and is difficult to penetrate cell membranes, especially the blood-brain barrier (BBB). In fact, the evaluation of pharmacological parameters shows that the blood-brain barrier penetration ability of Forsythia suspensa glycoside H is "low", indicating that its application in the treatment of central nervous system diseases may be limited, but it also reduces the risk of central nervous system toxicity.

In addition, pharmacological evaluation also showed that Forsythia suspensa glycoside H has no inhibitory effect on hERG potassium channels (hERG inhibition: no), which reduces its risk of causing cardiac QT interval prolongation and arrhythmia, and is a favorable safety signal. The Ames test result was 0.0, indicating that the compound did not exhibit mutagenicity in the bacterial recovery mutation test, suggesting that its genetic toxicity is relatively low. These physicochemical properties and preliminary safety data provide positive references for the subsequent development of Forsythia suspensa glycoside H. However, its high polarity and high molecular weight also suggest that formulation technology (such as nanocarriers and prodrug design) may need to be considered for oral administration to improve its bioavailability.

Plant sources and extraction methods

Forsythia suspensa glycoside H is mainly derived from the plant Forsythia suspensa in the family Rhinoceros（Forsythia suspensa The dried fruit of (Thunb.) Vahl, also known as Chinese medicine Forsythia suspensa. Forsythia suspensa is widely distributed in East Asia such as China, Japan, and South Korea, and is one of the commonly used medicinal herbs in clinical practice in China. Except for Forsythia suspensa, other plants of the same genus such as Golden Bell Flower（Forsythia viridissima）Or Qin Lianqiao（Forsythia giraldiana）It may also contain this ingredient, but the content is usually low. The content of Forsythia suspensa glycoside H in Forsythia suspensa varies depending on factors such as origin, harvest season, and processing method. It is generally believed that the content is higher in green Forsythia suspensa (immature fruit) than in old Forsythia suspensa (mature fruit).

The extraction method of Forsythia suspensa glycoside H is mainly based on its polarity characteristics, using solvent extraction method. The commonly used extraction solvents are water, methanol, ethanol, or their mixed solutions in different proportions. Due to the presence of multiple phenolic hydroxyl and sugar groups in the compound, it is sensitive to heat and acidity. Therefore, during the extraction process, it is usually necessary to control the temperature (such as room temperature or heating reflux but avoid prolonged high-temperature treatment) and pH value (neutral or weakly acidic environment). Traditional extraction methods include cold soaking, percolation, and heating reflux extraction. In order to improve extraction efficiency and selectivity, modern technologies such as ultrasound assisted extraction and microwave-assisted extraction have also been introduced in recent years. These methods can significantly shorten extraction time and increase the yield of target compounds.

The crude extract after extraction contains a large amount of impurities, such as sugars, proteins, pigments, and other phenolic compounds. Therefore, separation and purification are the key steps to obtain high-purity Forsythian glycosides H. Common separation and purification strategies include:

1. Liquid-liquid extraction Using different polar solvents (such as petroleum ether, ethyl acetate, n-butanol) to perform fractional extraction on the crude extract, and enriching forsythian glycoside H in the medium polarity n-butanol or ethyl acetate extraction layer.
2. column chromatography This is the most essential purification method. Common stationary phases include macroporous adsorption resins (such as D101, AB-8), silica gel, polyamide, ODS (C18 reverse phase silica gel), etc. Macroporous adsorption resin is commonly used for preliminary separation, which can effectively remove highly polar impurities such as sugars through ethanol water gradient elution at different concentrations. Subsequently, fine separation was performed using silica gel column chromatography (chloroform methanol water system) or ODS column chromatography (methanol water or acetonitrile water system).
3. High performance liquid chromatography (HPLC)For preparation grade purification, especially when obtaining high-purity (>98%) Forsythian glycoside H standard, preparative HPLC is often used. By using a C18 reverse phase column with acetonitrile water or methanol water (often with a small amount of formic acid or acetic acid added) as the mobile phase, efficient separation of the target compound can be achieved through isocratic or gradient elution.

In the separation process, the identification of compounds usually relies on nuclear magnetic resonance spectroscopy (NMR, including ¹ H-NMR, ¹ ³ C-NMR, 2D-NMR) and high-resolution mass spectrometry (HR-MS) techniques, which confirm their chemical structures by comparing with known literature data or standard standards.

Pharmacological activity research

The pharmacological activity research of Forsythia suspensa glycoside H mainly focuses on two fields: antiviral and anti-inflammatory, and there are also preliminary reports of antioxidant and immune regulatory activities.

1. Antiviral activity

Antiviral activity is one of the most concerned pharmacological activities of Forsythian suspensa glycoside H. Research has shown that Forsythia suspensa glycoside H has inhibitory effects on various viruses, and its mechanism of action involves multiple stages of the virus lifecycle.

• Anti herpes simplex virus (HSV) activity HSV-1 and HSV-2 are the main pathogens causing oral and genital herpes. Research has shown that Forsythia suspensa glycoside H can inhibit the replication of HSV. Its potential targets may include viral DNA polymerases (UL42, UL54) and immediate early protein ICP27. UL42 is an auxiliary subunit of HSV DNA polymerase, which is crucial for viral DNA replication; UL54 is the catalytic subunit of viral DNA polymerase. Forsythian glycoside H may interfere with the function of these enzymes and block the replication of the viral genome. In addition, ICP27 is an essential immediate early protein for HSV replication, involved in the processing and transport of viral mRNA. Inhibiting the function of ICP27 can significantly reduce the expression of viral proteins. Meanwhile, Forsythia suspensa glycoside H may also affect the activity of viral thymidine kinase (TK), which is an enzyme necessary for the activation of viral nucleoside analogue drugs such as acyclovir. However, the inhibition of TK by Forsythia suspensa glycoside H may be a non-specific effect, and its specific mechanism needs further clarification.

• Anti human immunodeficiency virus (HIV) activity Forsythian glycoside H also exhibits certain inhibitory potential against HIV. Its potential targets include HIV-1 protease (HIV1-PR) and integrase (INT). HIV-1 protease is responsible for cleaving viral precursor proteins into mature functional proteins and is an important target for anti HIV drugs. The integrase is responsible for integrating viral DNA into the host cell genome and is a key step in establishing persistent infection of the virus. Forsythian glycoside H may inhibit the catalytic function of these enzymes by binding to their active sites, thereby blocking the maturation and integration process of the virus. In addition, Forsythia suspensa glycoside H may also interfere with HIV virus entry into target cells by downregulating the expression of co receptors CCR5 and CXCR4 on the host cell surface. CCR5 and CXCR4 are necessary co receptors for HIV-1 to enter CD4+T cells. Blocking their binding to the viral envelope glycoprotein gp120 can effectively inhibit viral invasion.

• Antiviral activity against other viruses In addition to HSV and HIV, Forsythia suspensa glycoside H may also have inhibitory effects on other viruses such as respiratory syncytial virus (RSV) and influenza virus, but related research is not yet systematic. Its broad-spectrum antiviral potential deserves further exploration.

2. Anti inflammatory activity

Inflammation is a defense response of the body against injury and infection, but excessive or persistent inflammation can lead to tissue damage and various diseases. Forsythian glycoside H exhibits significant anti-inflammatory activity.

• Inhibit inflammatory mediators Research has shown that Forsythia suspensa glycoside H can inhibit the production of nitric oxide (NO), prostaglandin E2 (PGE2), and pro-inflammatory cytokines (such as TNF - α, IL-1 β, IL-6) in macrophages induced by lipopolysaccharide (LPS) or other inflammatory stimuli. These inflammatory mediators are key drivers of inflammatory response.
• Regulating key enzyme activity The anti-inflammatory effect of Forsythia suspensa glycoside H is closely related to its regulation of key inflammatory enzymes. Among them, inhibition of myeloperoxidase (MPO) is an important aspect of its anti-inflammatory activity. MPO is a heme peroxidase released by neutrophils and monocytes, which catalyzes the production of strong oxidants such as hypochlorous acid (HOCl) during inflammation, leading to tissue damage. Forsythian glycoside H can effectively inhibit the activity of MPO, thereby reducing oxidative stress-induced inflammatory damage.
• Action signal pathway The anti-inflammatory effect of Forsythia suspensa glycoside H also involves the regulation of multiple signaling pathways, such as nuclear factor kappa B (NF - κ B) and mitogen activated protein kinase (MAPK) pathways. It may inhibit the phosphorylation and degradation of I κ B α, prevent nuclear translocation of NF - κ B, and downregulate the expression of downstream pro-inflammatory genes. At the same time, it can also inhibit the phosphorylation of MAPKs such as p38, JNK, and ERK, reducing the synthesis of inflammatory factors.

3. Antioxidant activity

As a compound containing multiple phenolic hydroxyl groups, Forsythia suspensa glycoside H has direct antioxidant activity. It can eliminate various free radicals, such as hydroxyl radicals (· OH), superoxide anion radicals (O ₂⁻ ·), and DPPH radicals, and inhibit lipid peroxidation. This antioxidant activity is an important foundation for its anti-inflammatory properties and protection of cells from oxidative stress damage.

4. Other activities

Preliminary studies also suggest that Forsythia suspensa glycoside H may have immunomodulatory, antibacterial (especially against certain drug-resistant strains), and liver protective effects, but these activities require further experimental evidence to support.

Mechanism of action and molecular targets

The pharmacological activity of Forsythia suspensa glycoside H is the result of its interaction with multiple molecular targets. Based on existing research, its mechanism of action can be elucidated from two main aspects: antiviral and anti-inflammatory.

1. Mechanism of antiviral action

The antiviral effect of Forsythia suspensa glycoside H is not a single target, but is achieved through the synergistic action of multiple targets and links.

• Inhibit viral DNA replication Regarding HSV, Forsythia suspensa glycoside H may directly bind to the viral DNA polymerase complex (UL42/UL54), interfering with its catalytic activity and thus blocking the extension of the viral DNA strand. This mode of action is similar to nucleoside analogue drugs, but may act through different binding sites.
• Interference with viral gene expression By inhibiting the function of the immediate early protein ICP27, Forsythia suspensa glycoside H can interfere with the splicing, nuclear export, and translation of viral mRNA, thereby reducing the synthesis of viral proteins.
• Block virus maturation Regarding HIV, Forsythia suspensa glycoside H may competitively or non competitively inhibit the activity of HIV-1 protease (HIV1-PR), preventing the cleavage of the viral Gag Pol polyprotein and leading to the production of immature, non infectious viral particles.
• Inhibit virus integration By inhibiting the chain transfer activity of integrase (INT), Forsythia suspensa glycoside H can prevent the integration of viral cDNA into the host genome, thereby blocking the establishment of latent infection of the virus.
• Block virus invasion Forsythia suspensa glycoside H may interfere with the adsorption and membrane fusion process between the virus and host cells by downregulating the expression of CCR5 or CXCR4 co receptors on the host cell surface, or directly binding to viral envelope glycoprotein gD (HSV) or gp120 (HIV).

2. Anti inflammatory mechanism

The anti-inflammatory mechanism of Forsythia suspensa glycoside H mainly involves the regulation of inflammatory signaling pathways and key enzyme activities.

• Inhibition of NF - κ B pathway NF - κ B is the core transcription factor of inflammatory response. Forsythia suspensa glycoside H can inhibit the activity of upstream kinases (such as IKK), prevent the phosphorylation and ubiquitination degradation of I κ B α, and retain NF - κ B (p65/p50) dimers in the cytoplasm, preventing them from entering the nucleus to initiate the transcription of pro-inflammatory genes (such as iNOS, COX-2, TNF - α, IL-6).
• Inhibition of MAPK pathway Forsythian glycoside H can inhibit the phosphorylation of p38, JNK, and ERK1/2. These MAPK pathways play a critical role in the synthesis of inflammatory factors and cellular stress responses. Inhibiting these pathways can reduce the activity of transcription factors such as AP-1, thereby reducing the production of inflammatory mediators.
• Directly inhibit MPO activity The phenolic hydroxyl structure of Forsythia suspensa glycoside H may make it a substrate or inhibitor of MPO. It can bind to the active site of MPO, competitively inhibiting its reaction with natural substrates such as chloride ions, thereby reducing the production of strong oxidant hypochlorous acid (HOCl), alleviating oxidative stress and inflammatory damage.
• Adjust the redox balance By directly clearing reactive oxygen species (ROS) and reactive nitrogen species (RNS), Forsythia suspensa glycoside H can reduce intracellular oxidative stress levels, thereby weakening the activation of ROS mediated inflammatory signaling pathways such as NF - κ B and MAPK.

3. Summary of molecular targets

Overall, the molecular target network of Forsythia suspensa glycoside H includes:

• Virus target UL42, UL54, ICP27, TK, gD of HSV; HIV1-PR, INT, CCR5, CXCR4 of HIV.
• Host target MPO, NF - κ B pathway related proteins (IKK, I κ B α, p65), MAPK pathway related proteins (p38, JNK, ERK).

This multi-target mode of action is a major advantage of natural products, which can reduce the risk of virus resistance and simultaneously exert dual anti-inflammatory and antiviral effects.

Evaluation of drug properties and pharmacokinetics

The pharmacological evaluation of Forsythia suspensa glycoside H is a key step in pushing it from the laboratory to clinical application. Based on its physicochemical properties and preliminary pharmacokinetic studies, a preliminary evaluation of its potential as a drug can be conducted.

1. Evaluation of drug properties

• Analysis of drug properties According to the Lipinski Five Rules, the molecular weight of Forsythia suspensa glycoside H (624.59 Da) exceeds 500, the LogP (0.26) is less than 5, the number of hydrogen bond donors (phenolic and alcohol hydroxyl groups, approximately 10) exceeds 5, and the number of hydrogen bond acceptors (approximately 15) exceeds 10. Therefore, it violates three of Lipinski's rules (molecular weight, hydrogen bond donor, hydrogen bond acceptor), suggesting that its oral bioavailability may be poor. The high TPSA value (245.29 Å ²) also confirms its high polarity and difficulty in transmembrane transport.
• safety assessment The preliminary safety data is relatively optimistic. HERG inhibition negative reduces the risk of cardiac toxicity; A negative Ames test indicates no direct mutagenicity. However, these are only preliminary in vitro and predictive data. A comprehensive safety evaluation requires further toxicological studies on acute toxicity, subchronic toxicity, reproductive toxicity, and genetic toxicity in vivo.
• Metabolic stability Forsythia suspensa glycoside H contains multiple glycosidic and ester bonds, which are easily hydrolyzed by enzymes in the gastrointestinal tract and liver. After oral administration, it may be metabolized by intestinal microbiota or esterases and glycosidases in the liver, producing aglycones (such as hydroxytyrosol) or smaller fragments. These metabolites may have different biological activities. Therefore, its metabolic stability is a key factor affecting oral bioavailability.

2. Pharmacokinetic characteristics

At present, there are few direct studies on the pharmacokinetics of Forsythia suspensa glycoside H in vivo. However, based on its structural analogues (such as Forsythia suspensa glycoside A) and physicochemical properties, some characteristics can be inferred:

• absorb Due to its large molecular weight and strong polarity, the oral absorption of Forsythia suspensa glycoside H may be poor, resulting in low bioavailability. Its absorption may mainly occur in the small intestine, but requires the use of transporters (such as glucose transporters) or through cellular pathways. Its water solubility is good (LogS 5.2), which is beneficial for dissolution in gastrointestinal fluids, but its transmembrane ability is weak.
• distribution Due to its high polarity and low fat solubility, the distribution volume of Forsythia suspensa glycoside H may be relatively small, mainly distributed in extracellular fluid. Its blood-brain barrier penetration ability is low, which limits the distribution of the central nervous system, but also reduces central toxicity. It may be mainly distributed in organs with abundant blood flow and metabolic excretion such as the liver, kidneys, and lungs.
• Metabolism Forsythian glycoside H may undergo extensive metabolism in the body. The main metabolic pathways include: ① hydrolysis Esters and glycosidic bonds are hydrolyzed by esterases and glycosidases to produce caffeic acid, hydroxytyrosol, and glycosyl moieties; ② Combination reaction The phenolic hydroxyl group may undergo II phase metabolic reactions such as glucuronidation, sulfation, or methylation; ③ redox The benzene ring and side chains may undergo redox reactions. These metabolites may have different pharmacological activities or toxicity.
• excretion Forsythian glycoside H and its metabolites are mainly excreted through bile and urine. Due to its large molecular weight and high polarity, bile excretion may be its main clearance pathway. Renal excretion may also be involved, but it requires tubular secretion or filtration.

3. Strategies for improving drug properties

Given the potential low oral bioavailability of Forsythia suspensa glycoside H, future drug development may require the following strategies:

• Prodrug design By chemically modifying its phenolic hydroxyl or carboxyl groups (such as esterification or phosphorylation), a prodrug is prepared to improve its lipid solubility and membrane permeability, and the original drug is released after enzymatic hydrolysis in vivo.
• New formulation technology Using nanotechnology, such as liposomes, polymer nanoparticles, solid lipid nanoparticles, or phospholipid complexes, to encapsulate Forsythia suspensa glycoside H, improving its solubility, stability, and oral absorption rate.
• Simplification and optimization of structure Using Forsythia suspensa glycoside H as the lead compound, through structure-activity relationship studies, we aim to find derivatives with simpler structures, stronger activity, and better drug properties. For example, retaining the key caffeoyl and phenylethanol structures and simplifying the sugar moiety.
• Non oral administration route Consider developing non oral dosage forms such as injections, transdermal patches, or nasal sprays to bypass first pass effects and absorption barriers and directly exert drug efficacy.

Clinical application prospects and prospects

The unique antiviral and anti-inflammatory dual activity of Forsythia suspensa glycoside H has shown potential clinical application prospects in multiple therapeutic fields.

1. Antiviral therapy

• Herpesvirus infection The inhibitory effect of Forsythia suspensa glycoside H on HSV, especially its multi-target action on viral DNA polymerase and ICP27, makes it a potential new drug for the treatment of oral and genital herpes. Compared with existing nucleoside drugs such as acyclovir, it may have different resistance mechanisms and may also be effective against drug-resistant virus strains. In addition, its anti-inflammatory activity helps alleviate local inflammatory reactions caused by herpes.
• HIV infection The inhibition of HIV-1 protease and integrase by Forsythia suspensa glycoside H, as well as its regulatory effect on CCR5/CXCR4, make it a potential candidate component for anti HIV combination therapy. As a natural product, it may have low toxicity and good safety, making it suitable for long-term use. However, its anti HIV activity may be limited and needs to be combined with other anti HIV drugs.
• Other viral infections Given its broad-spectrum antiviral potential, Forsythia suspensa glycoside H is also worth exploring in the treatment of respiratory viral infections (such as influenza, RSV) and emerging viruses (such as certain coronaviruses).

2. Inflammatory diseases

• Inflammatory skin disease The anti-inflammatory and antioxidant activities of Forsythia suspensa glycoside H, especially its inhibition of MPO, make it potential for the treatment of inflammatory skin diseases characterized by neutrophil infiltration and oxidative stress, such as psoriasis and atopic dermatitis. Topical preparations may be an ideal mode of administration.
• Chronic inflammatory diseases For chronic inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease, Forsythia suspensa glycoside H may exert therapeutic effects by inhibiting the NF - κ B and MAPK pathways, reducing the production of pro-inflammatory cytokines. However, its low oral bioavailability is the main obstacle and requires the use of new formulation technologies.
• Acute lung injury/acute respiratory distress syndrome (ALI/ARDS)In ALI/ARDS caused by infection or trauma, excessive inflammatory response and oxidative damage are the core pathological processes. The anti-inflammatory and antioxidant properties of Forsythia suspensa glycoside H may help alleviate lung inflammation and edema, and protect lung function.

3. Outlook and Challenges

Although Forsythia suspensa glycoside H has broad prospects, its translation from laboratory to clinical still faces many challenges:

• Pharmacokinetic bottleneck Low oral bioavailability is the biggest obstacle. How to effectively increase its in vivo exposure through formulation technology or structural modification is the focus of future research.
• In depth analysis of the mechanism of action Although multiple targets have been identified, their precise binding modes, affinities, and synergistic mechanisms between different targets still need to be further elucidated through advanced technologies such as molecular docking, surface plasmon resonance (SPR), and cellular thermal transition analysis (CETSA).
• In vivo efficacy verification Currently, most pharmacological activity research remains at the cellular level. It is necessary to systematically validate its in vivo efficacy and safety in various animal models, such as HSV infected mouse models, LPS induced inflammation models, and collagen induced arthritis models.
• Study on Structure Activity Relationship Systematically study the structure-activity relationship of Forsythia suspensa glycoside H and its analogues (such as Forsythia suspensa glycoside A, B, C, etc.), clarify which structural fragment (caffeoyl, phenylethanolic, glycosyl) contributes the most to specific activity, and provide guidance for structural optimization.
• Quality Control and Large Scale Production Establishing a stable, efficient, and low-cost extraction and purification process, and establishing strict quality standards (including content determination, fingerprint analysis, impurity control), is the foundation for ensuring subsequent research and development.

Conclusion

Forsythia suspensa glycoside H, as an important caffeoylphenylethanolic glycoside in Forsythia suspensa, has shown significant research value and development potential in the fields of antiviral and anti-inflammatory due to its unique chemical structure and multi-target pharmacological mechanism of action. It achieves dual antiviral and anti-inflammatory effects by inhibiting key viral replication enzymes (such as UL42, UL54, HIV1-PR, INT) and host inflammatory signaling pathways (NF - κ B, MAPK) and key enzymes (MPO). This synergistic effect has unique advantages in treating viral infections and their associated inflammatory complications.

However, the pharmaceutical challenge of Forsythia suspensa glycoside H, especially its low oral bioavailability caused by its high polarity, is the main bottleneck facing its clinical translation. Future research should focus on: 1) utilizing modern medicinal chemistry and nanotechnology to develop prodrugs or novel delivery systems to improve their pharmacokinetic properties; 2) Thoroughly elucidate its metabolic pathways and active metabolites in the body; 3) Validate its efficacy and safety in various in vivo disease models; 4) The system conducts structure-activity relationship research to provide a basis for discovering better candidate drugs.

In summary, Forsythia suspensa glycoside H is a natural product lead compound worthy of further investigation. Although the road from laboratory to clinical application is still long and challenging, with the interdisciplinary integration and technological advancement, Forsythia suspensa glycoside H and its derivatives are expected to become a new choice for treating viral infections and inflammatory diseases in the future, contributing to human health.